Serum AFP · Surveillance · Relapse · Chemotherapy Summary Background: The aim of this study was to assess fluctuations in normal serum alpha-fetoprotein (AFP) levels in patients with germ cell cancer. Marked variations occur after serum AFP levels normalize, creating anxiety among patients and physicians during surveillance. Patients and Methods: We conducted a retrospective review of patients with germ cell tumors in clinical remission, who had normal AFP levels and were followed at our center from 1991 to 2009. 72 patients, with a median follow-up of 50 months, were identified. Results: Of the 72 patients, 57 (79%) had a non-seminomatous germ cell histology, and 15 (21%) had seminomas. Seminomas were included as controls as serum AFP levels do not increase in this group. 68 patients underwent orchiectomy, and 50 patients received systemic chemotherapy. The majority of patients (93%) demonstrated fluctuations in serum AFP. There was no difference in the mean AFP values between patients with seminona (2.95 ng/ml) and those with non-seminomatous germ cell tumors (3.3 ng/ml) (standard deviation 1.01 ng/ml). Conclusion: Marked variations occur after serum AFP levels normalize in patients undergoing surveillance. Fluctuating AFP levels within normal limits did not result in relapse in our cohort of patients with extended follow-up.
Introduction
Testicularcanceraccountsfor1-2%ofallneoplasmsinmen [1] . It is the most common malignancy in otherwise healthy men 20-35 years of age and has an annual incidence of approximately 4 per 100,000 [2] . Tumor markers such as alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (bHCG) have an established role in the management of testicular cancer [3, 4] . They are used for diagnosis and prognosis, monitored during therapy, and are followed after completionoftherapyforrelapse [5] . Onkologie2012; 35:588-591 VariationsinSerumAFPinPatients withTesticularCancerduringSurveillance 589 Tothepatientsthatreceivedsystemicchemotherapy,acombination ofaplatinumagent,etoposide,andbleomycinwasgivenevery3weeks foratotalof3or4cycles.SubsequentregimensincludedTIP (paclitaxel, ifosfamide, cisplatin) or VIP (etoposide, ifosfamide, cisplatin) . Patients undergoing surveillance were followed according to National ComprehensiveCancerNetwork(NCCN)guidelines.Relapsewasidentifiedby abnormalclinicalexam,risingtumormarkers,orradiographicimaging.
From a total of 176 patients, 72 were considered eligible for the studybasedonthefollowingcriteria:i)norelapseandnormalAFPlevels (< 10 ng/ml); ii) histological documentation of germ cell cancer from orchiectomyspecimensatourinstitution;iii)undergoingregularfollowup visits; iv) complete clinical and radiographic follow-up with serum AFP determinations and/or radiographic scans at regular intervals; v)clinicalandradiographicdeterminationofdiseasestatusatthetimeof lastfollow-uporrecurrence.
We included patients with seminoma in our analysis to serve as a control group since elevations in AFP levels are not expected in this histology but are routinely obtained both at diagnosis and subsequent follow-up.WeevaluatedserumAFPlevelsforeachpatientfromthetime thattheAFPlevelnormalizedtolastfollow-up.Thestudyprotocolwas evaluated and approved by the Institutional Review Board at Stanford University.
Statistical Analysis
For each subject, the mean AFP level was calculated using every AFP measurementstartingfromthedatewhenAFPreachedanormallevelor less, until the date of last contact, up to 10 years. Differences in group scores were assessed with unpaired t-tests, and effects were considered statisticallysignificantwithapvalue<0.05.Allanalyseswereconducted withSAS9.2TS2M3(SASInstituteInc.,Cary,NC,USA).
Results
Ofthe72patients,57(79%)hadanon-seminomatousgerm cellhistologyand15(21%)hadseminomas(table1).33%of patients were stage I, 6% were stage Is, 28% were stage II, and33%werestageIII.68patientsunderwentorchiectomy, and 50 patients received systemic chemotherapy. 4 patients hadextragonadalprimaries.3patientsrequiredahematopoi-eticstemcelltransplant.Themeanageofpatientsatdiagnosiswas30.6years.Medianfollow-upwas52months.Overall, each patient had an average of 12.76 samples (range 1-39) over 3.5 years (range 127-3,526 days) . Figure 1 shows the trajectoryofAFPscoresforeachindividualpatient.Almost all patients had fluctuations within the normal range during thefollow-upperiod.Ofthe57patientswithNSGCT,1had no fluctuation. The remaining 56 patients had significant variations, but none relapsed within the long follow-up period.Ofthe15patientswithseminomainwhomAFPlevels arenotexpectedtorise,13patientsdemonstratedfluctuations inAFPlevelsandnonerelapsed( fig.2 ).ThemeanAFPvalue acrossallsampleswas3.18ng/ml(range0.80-10ng/ml)witha standard deviation (SD) of 1.73 ng/ml. Furthermore, there wasnoevidenceofadifferenceinthemeanAFPvaluesbetween patients with seminona (2.95 ng/ml) and those with non-seminomatousgermcelltumors(3.36ng/ml)(p<0.31).
Physiologically, AFP is mainly produced in the liver and the yolk sac of human fetuses more than 4 weeks old, with peakvaluesofupto4mg/mlat12-16weeksofgestation [6, 7] . With a half life of 5 days, AFP levels fall within 8-12 monthsafterbirthtoaverylowconcentrationof<10ng/ml andpersistatlowlevelsthroughoutlife [8, 9] .Normaladult levels remain at approximately 2-4 ng/ml [10] . AFP is producedinapproximatelytwo-thirdsofthepatientswithgerm celltumorscontainingyolksacelements(embryonalcarcinomasandendodermalsinustumors).90%ofpatientswithnon-seminomatousgermcelltumors(NSGCT)atanystageofthe diseasehaveelevatedserumlevelsforAFP,bHCG,orboth before treatment. Seminoma tumors do not increase AFP levels and occasionally increase bHCG levels. Persistent marker elevation after chemotherapy indicates persistent diseaseandtheneedforfurthertherapy [11] .Patientsarefollowedquiterigorouslywithtumormarkers,physicalexamination, and computed tomography (CT) scans for a period of 5yearsafterorchiectomy,retroperitoneallymphnodedissection (RPLND), or chemotherapy [12] . Most relapses occur withinthefirstyear,andrelapsesafter2yearsarerare.These relapsesaredetectedbeforeclinicalsymptomsappear.
FluctuationsinserumAFPlevelswithinthenormalrange occurinpatientsduringthisfollow-upperiod,causinganxiety about relapse. Patients frequently question the significance of an increase in AFP within normal levels and whether it predicts for relapse. We seek to evaluate the variations and fluctuationsinserumAFPlevelsafteritnormalizesthatoccur inpatientsduringtheirfollow-upsurveillanceperiod.
Patients and Methods
We conducted a retrospective review of all patients with germ cell tumors, who were in clinical remission (defined as normal scans and normal markers) and followed with surveillance. This includes patients who have had an orchiectomy alone, those with an RPLND, and those treatedwithchemotherapyinadditiontoorchiectomy.Allpatientshad AFPlevelsdrawnattheStanfordUniversityCancerCenterfrom1991to 2009. Patients were identified from pathology specimens after orchiectomyaswellasfromourelectronicmedicalrecorddatabase.
Patients were screened retrospectively for their initial serum AFP level, age, site of disease, date of diagnosis, tumor histology and grade, stageofdisease,theavailabilityofserialserumAFPleveldeterminations, and disease status at last follow-up. Treatments including orchiectomy, surveillance, chemotherapy, retroperitoneal lymph node dissection, and radiation were documented. Stage of disease was based on the TNM Classification of Malignant Tumors as published in the AJCC Cancer StagingManual.
Patientchartswerereviewedforacompletehistory,physicalexamination, appropriate imaging studies (chest X-ray, CT, magnetic resonance imaging, and positron emission tomography), and serum AFP levels. SerumAFPlevelsweremeasuredpre-operativelyandduringsurveillance. TheserumlevelsofAFPweredeterminedusinganAFPenzymeimmunoassay (Siemens AFP ADVIA Centaur Immunoassay Systems, Siemens Deerfield, IL, USA) according to the manufacturer's instruction. All serumsampleswereanalyzedinthesamelaboratoryatStanford Hospital. TheupperlimitofnormalofserumAFPwas10ng/mlatourinstitution.
Discussion
Tumor markers are of central importance in the diagnosis, staging, risk assessment, and monitoring of patients with testicularcancer.RisinglevelsofAFPabovenormalindicate persistentgermcelltumorevenintheabsenceofradiographic evidence of disease. Various malignancies rely on the use of tumor markers for early indications of disease activity in patients who achieve a complete clinical response after primary treatment. In ovarian cancer, different prognostic groupings exist within the commonly regarded normal CA-125 range, where the upper limit of normal is 35 U/ml. In a group of ovarian cancer patients in complete clinical remission,Santillanetal. [13] reportedthatprogressive,lowlevelincreaseinserumCA-125levelsisstronglypredictiveof radiographic disease recurrence. The specific patterns of increase investigated were an absolute increase of 5 U/ml fromnadir,anabsoluteincreaseof10U/mlfromnadir,and doublingoftheCA-125nadir.Inanupdatedanalysis,patients withCA-125levelsintherangeof<10,10-20,and21-35U/ ml had a different risk of progression. The median progression-freesurvivalofthe3groupswas58,45,and37months, respectively [14] .
Inourstudy,themajorityofpatientshadanon-seminomatoushistologyandstageIIorIIIdisease.Mosthadanorchiectomy followed by a systemic chemotherapy regimen. 67 (93%) patients in our cohort had fluctuations in serum AFP within normal levels. Exploratory visualization of the data did not show any evidence of a pattern in AFP. The mean AFP value across all samples was 3.18 ng/ml (range 0.80-10 ng/ml) with an SD of 1.73 ng/ml. Thus, variations withinthenormalrangewereverycommon,withamajority of patients having fluctuations in normal serum AFP levels. Toourknowledge,thishasneverbeenreportedpreviously. Ourstudywaslimitedduetoitssmallsamplesizeaswellas selection bias. Given the long follow-up of the patients who have not relapsed, it is reassuring that variations of serum AFPwithinnormallevelswerecommonanddidnotindicate arelapse.Thepatientsthatwereincludedforourreviewwere those that had adequate laboratory data and were able to participateinregularclinicvisitsandtestingforsurveillance. We used patients with seminoma as a control group as we wouldnotexpectAFPvaluestobeelevatedinthishistology eventhoughlaboratorytestingisroutinelyperformedinthe clinicalpracticesetting.Ourretrospectivereviewofpatients withtesticularcancerwhileonsurveillanceshowshighfluctuationsinthelevelofserumAFPonceithasreachednormal values. The pattern of fluctuation was not helpful in predicting relapse. Patients should be reassured that a majority does have fluctuations within normal values which do not necessarilyresultinarelapse. 
